AstraZeneca’s Covid vaccination trial in children revealed a risk of 15 adverse events – see the complete list
The Covid vaccination is currently being tested on 300 children aged six to seventeen by CORONAVIRUS research, which is financed by AstraZeneca and the National Institute of Health Research.
“Immunizing youngsters is likely to be a critical step in gaining control of the pandemic in the UK,” the University of Oxford researchers said, adding that it will assist to protect vulnerable adults like teachers and carers. The trial’s organizers stated, “This study will provide us with significant information on the vaccine’s safety features as well as its capacity to induce good immune responses against the virus in this age range.” Parents who lived near one of the four trial centers were allowed to sign up their children for the study.
Participants in this study had to be 16 or 17 years old to consent to their own participation.
The trial’s participants were expected to have “no substantial medical history.”
240 of the 300 individuals will receive the candidate vaccination ChAdOx1 nCoV-19, while the remaining 60 will receive a placebo.
Participants will be unaware of which group they are in, according to the researchers.
As a result, the children will have no idea whether they received the actual Covid vaccine or a placebo.
Blood tests will be performed on the young volunteers, but the skin will be numbed with an anesthetic lotion to make the procedure as painless as possible.
Parents should be informed, however, that their children may develop negative effects after receiving the vaccine.
The researchers identified a number of “very common” side effects that can be expected in more than one out of every ten subjects, including:
Other “common” vaccination adverse effects could include:
Despite the fact that it is “uncommon,” the kid may face the following dangers:
While the disadvantages of participating in the experiment are obvious, so are the benefits.
“Knowledge gathered from this investigation will help us create a vaccine against the newly emerging coronavirus disease COVID-19,” the researchers wrote.
Furthermore, the findings may “support future approval of this vaccine for use in children.”
Furthermore, after participating in this study, the patients and their caregivers/parents may be protected from Covid.
This is due to the vaccine’s efficiency against infection in adults, which has been reported to be 60-90 percent.
Participants would receive a £10 reimbursement for each research visit to cover travel expenses incurred while taking part in the study. “Brinkwire News in Condensed Form.”